Trial
NCT05690035
Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Sun Yat-sen University
Collaborators
Hutchmed; BeiGene
Condition
Metastatic Colorectal Cancer
Intervention
Tislelizumab & Fruquintinib
Why stopped
Due to slow patient recruiting. No patients were enrolled 12 months after study initiation.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-09